Why the study?
Although influenza vaccination reduces MACE in cardiovascular disease, vaccination coverage for US individuals with heart disease was only 48% in the 2015-16 season.
Does increasing influenza vaccination coverage to 75% improve cost-effectiveness and prevent MACE readmissions in US ACS patients?
Population
Estimated 493,750 US ACS patients
Comparison
Increased influenza vaccination coverage (75% to 95%) vs current US coverage
Design
Monte Carlo decision-tree cost-effectiveness model
Authors
Loading...
Modeling suggests higher influenza vaccination may be cost-effective for MACE prevention in CVD; leaves open real-world uptake and savings.
Does increasing influenza vaccination coverage to 75% improve cost-effectiveness and prevent MACE readmissions in US ACS patients?
Increasing influenza vaccination rates to at least 80% among hospitalized ACS patients is cost-saving and averts additional MACE readmissions.
Peasah et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: